This report provides an overview of the Parkinson’s Disease (PD) biomarkers landscape, with a focus on biochemical and molecular based assays that MJFF staff is monitoring. It is intended to reflect biomarkers at various stages of development and validation for the indicated intended uses (e.g., diagnosis, monitoring, etc.) Although MJFF and the field are actively pursuing discovery-based efforts, these will not be included in this report until key 'hits' have been identified and individual measures can be moved through this pipeline. Finally, some biomarkers currently under development are not reflected here due to confidentiality. Internally, MJFF is leveraging this report to identify critical gaps in our portfolio and monitor progression of promising measures moving towards qualification. This will help shape MJFF’s biomarkers vision and strategy and ensure transparency and communication across efforts. Externally, this report will serve as a resource to our partners who may be interested in MJFF’s biomarkers portfolio and opinion on the state of the field. It could also be used to help determine which biomarker(s) may be relevant to include as exploratory endpoints in clinical trials. The report will be updated and distributed on an annual basis.

Reviewer Acknowledgements: Brit Mollenhauer, Kalpana Merchant, Doug Galasko, David Standaert, Andrew Howden, Caroline Williams-Gray, Venissa Machado, Daniel Ysselstein, Anastasia Henry, Ian Reynolds